Interpace Diagnostics Group, Inc.
(NASDAQ : IDXG)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Services » Servicestothe Health Industry
symbolcompany%chnglast%shortavg$volume
ESRXExpress Scripts Holding Company
0.19%56.925.9%$214.58m
DGXQuest Diagnostics Incorporated
0.26%91.774.2%$155.20m
CERNCerner Corporation
0.72%72.607.4%$147.36m
QQuintiles Transnational Holdings, Inc.
0.15%99.484.4%$128.60m
LHLaboratory Corporation of America Holdings
-0.16%149.432.3%$97.53m
ATHNathenahealth, Inc.
2.40%118.1018.0%$55.88m
ABCOAdvisory Board Company
-0.14%53.786.1%$44.86m
INCRINC Research Holdings, Inc. Class A
-2.42%54.403.4%$42.67m
SRCLStericycle, Inc.
1.46%71.096.7%$40.33m
HLSHealthSouth Corporation
0.00%45.129.4%$29.24m
MDRXAllscripts Healthcare Solutions, Inc.
0.72%13.929.4%$28.40m
HCSGHealthcare Services Group, Inc.
0.16%54.546.8%$25.23m
OMCLOmnicell, Inc.
0.05%50.7311.5%$10.96m
HMSYHMS Holdings Corp.
-0.16%18.891.9%$9.42m
HSTMHealthStream, Inc.
-0.34%23.646.8%$4.05m

Company Profile

Interpace Diagnostics Group, Inc. engages in the development and commercialization of molecular diagnostic test. It focuses on early detection high potential progresses to cancer. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.